JSP191 Antibody Targeting Conditioning in SCID Patients
← catalyst calendarSponsored by Jasper Therapeutics, Inc. (industry) · JSPR — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
23actual
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-03-20 | actual | When the study began enrolling |
| Primary completion | 2025-07-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-07 | actual | The whole study's end, after follow-up |
| First posted | 2016-11-15 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- SCID
Intervention
- Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Safety and tolerability of JSP191 as conditioning therapy in SCID patients undergoing HCT: adverse events
measured Up to 5 years post Donor Cell Transplant (28 days dose limiting toxicity period)
Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients
measured Up to 24 weeks post Donor Cell Transplant
Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients
measured Weeks 36-104 post Donor Cell Transplant
Permalink · JSPR's whole pipeline · Catalyst calendar · Every registered study · What changed